EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas

Oncologist

Volumn 17, Issue 7, 2012, Pages 978-985

  Chen, Zhi Yong ^a   Zhong, Wen Zhao ^a   Zhang, Xu Chao ^a   Su, Jian ^a   Yang, Xue Ning ^a   Chen, Zhi Hong ^a   Yang, Jin Ji ^a   Zhou, Qing ^a   Yan, Hong Hong ^a   An, She Juan ^a   Chen, Hua Jun ^a   Jiang, Ben Yuan ^a   Mok, Tony S ^b   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Epidermal growth factor receptor; Heterogeneity; Lung neoplasm; Metastasis

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB;

ADULT; AGED; ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; DISEASE CLASSIFICATION; DNA SEQUENCE; FEMALE; GENETIC HETEROGENEITY; GENOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC HETEROGENEITY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84864045330     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0385     Document Type: Article

References (30)

1. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
2. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
3. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with nonsmall-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11: 121-128.
4. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006;12:7242-7251.
5. Cohen MH, Williams GA, Sridhara R et al. United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218.
6. Cohen MH, Johnson JR, Chen YF et al. FDA drug approval summary: Erlotinib (Tarceva) tablets. The Oncologist 2005;10:461-466.
7. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
8. Ryoo BY, Na II, Yang SH et al. Synchronous multiple primary lung cancers with different response to gefitinib. Lung Cancer 2006;53:245-258.
9. Park KY, Jung JW, Nam SB et al. Two lung masses with different responses to pemetrexed. Korean J Intern Med 2010;25:213-216.
10. Taniguchi K, Okami J, Kodama K et al. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008;99:929-935.
11. Jiang SX, Yamashita K, Yamamoto M et al. EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. Int J Cancer 2008;123:2480-2486.
12. Wang X, Wang M, MacLennan GT et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst 2009;101:560-570.
13. Chang YL, Wu CT, Shih JY et al. Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. Ann Surg Oncol 2011;18: 543-550.
14. Schmid K, Oehl N, Wrba F et al. EGFR/KRAS/ BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009;15:4554-4560.
15. Pirker R, Herth FJ, Kerr KM et al. Consensus for EGFR mutation testing in non-small cell lung cancer: Results from a European workshop. J Thorac Oncol 2010;5:1706-1713.
16. Krypuy M, Newnham GM, Thomas DM et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006;6:295.
17. Kalikaki A, Koutsopoulos A, Trypaki M et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008;99:923-929.
18. Zhou Q, Zhang XC, Chen ZH et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011;29:3316-3321.
19. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011;29:2972-2977.
20. Gow CH, Chang YL, Hsu YC et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 2009;20:696-702.
21. Park S, Holmes-Tisch AJ, Cho EY et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in nonsmall cell lung cancer. J Thorac Oncol 2009;4:809-815.
22. Zhong WZ, Wu YL, Yang XN et al. Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. Clin Lung Cancer 2010;11:160-168.
23. Nakano H, Soda H, Takasu M et al. Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 2008; 60:136-140.
24. Chang YL, Wu CT, Lin SC et al. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin Cancer Res 2007;13:52-58.
25. Ma ES, Cheng PN, Wong CL et al. Synchronous primary lung cancer and epidermal growth factor receptor mutation. Ann Thorac Surg 2010;90:e38-e39.
26. Chung JH, Choe G, Jheon S et al. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol 2009;4: 1490-1495.
27. Girard N, Deshpande C, Azzoli CG et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: Comparison with clinical guidelines. Chest 2010; 137:46-52.
28. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
29. Oxnard GR, Arcila ME, Chmielecki J et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011;17:5530-5537.
30. Cheng H, An SJ, Dong S et al. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. J Hematol Oncol 2011;4:5.